中文
Nanjing Delova Biotech Co., Ltd.
A Global Leader in Pain Management Drug Innovation
Nanjing Delova Biotech Co., Ltd. is a global biopharmaceutical company focused on the development of innovative new drugs for pain management. Targeting unmet clinical needs worldwide, we aim to provide patients with non-opioid, long-acting, and potent analgesic therapies, improving human health through scientific innovation.
Learn More
Pipeline

1product

approved and marketed in both China and the U.S.

10projects+

currently in development

Achievements

4

IND approvals

15

clinical trials initiated

Patent Filings

30+

international patents

40+

domestic patents

  • Product Showcase
  • Research Pipeline
Putanning®
——
Meloxicam Injection (II)

Developed using the company's proprietary solubilization technology platform, the product was simultaneously approved in China and the U.S. in April 2025. It is China's first 24-hour long-acting, once-daily NSAID injection for postoperative pain and the first 2.2-class new postoperative analgesic drug approved in the country.

Learn More
Research Pipeline
Focusing on unmet clinical needs in China and the U.S., Delova has established a pipeline of over 10 novel non-opioid analgesic candidates. These products are gradually entering clinical development and registration stages. The company has filed over 70 core invention patents related to pipeline products, with 20+ patents granted.
Approved Products

Putanning®

Meloxicam Injection II

QAMZOVA™
Pipeline in Development

QP002

China's first 3-day long-acting fixed-combination drug for local analgesia

QP-6211

World's first 1-week extended-release local anesthetic.

QP-5113

China's first 3-month ultra-long-acting topical formulation

Other projects pending disclosure

News

Learn More

We offer a challenging, rewarding, and fast-growing career.

We welcome those who share our vision！

HR@delovabio.com

Learn More
Search
X